A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern

A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern

ABSTRACT CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO). Previous studies reported increased levels of neutralizing antibodies and specific T cells 2 and 4 weeks after two doses of CoronaVac; these levels were significantly reduced at 6 to 8 months aft...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Bárbara M. Schultz, Felipe Melo-González, Luisa F. Duarte, Nicolás M. S. Gálvez, Gaspar A. Pacheco, Jorge A. Soto, Roslye V. Berríos-Rojas, Liliana A. González, Daniela Moreno-Tapia, Daniela Rivera-Pérez, Mariana Ríos, Yaneisi Vázquez, Guillermo Hoppe-Elsholz, Catalina A. Andrade-Parra, Omar P. Vallejos, Alejandro Piña-Iturbe, Carolina Iturriaga, Marcela Urzua, María S. Navarrete, Álvaro Rojas, Rodrigo Fasce, Jorge Fernández, Judith Mora, Eugenio Ramírez, Aracelly Gaete-Argel, Mónica L. Acevedo, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Daniela Weiskopf, Alba Grifoni, Alessandro Sette, Gang Zeng, Weining Meng, José V. González-Aramundiz, Pablo A. González, Katia Abarca, Alexis M. Kalergis, Susan M. Bueno
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: American Society for Microbiology 2022-08-01
Sarja:mBio
Aiheet:
CoronaVac
phase III clinical trial
SARS-CoV-2
COVID-19
booster dose
Linkit:https://journals.asm.org/doi/10.1128/mbio.01423-22

Internet

https://journals.asm.org/doi/10.1128/mbio.01423-22

Samankaltaisia teoksia